作者
Hiroyuki Yasuda, Eunyoung Park, Cai-Hong Yun, Natasha J Sng, Antonio R Lucena-Araujo, Wee-Lee Yeo, Mark S Huberman, David W Cohen, Sohei Nakayama, Kota Ishioka, Norihiro Yamaguchi, Megan Hanna, Geoffrey R Oxnard, Christopher S Lathan, Teresa Moran, Lecia V Sequist, Jamie E Chaft, Gregory J Riely, Maria E Arcila, Ross A Soo, Matthew Meyerson, Michael J Eck, Susumu S Kobayashi, Daniel B Costa
发表日期
2013/12/18
期刊
Science translational medicine
卷号
5
期号
216
页码范围
216ra177-216ra177
出版商
American Association for the Advancement of Science
简介
Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non–small cell lung cancer (NSCLC). However, EGFR exon 20 insertion mutations (~10% of all EGFR mutations) are generally associated with insensitivity to available TKIs (gefitinib, erlotinib, and afatinib). The basis of this primary resistance is poorly understood. We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. The crystal structure of a representative TKI-insensitive mutant (D770_N771insNPG) reveals an unaltered adenosine triphosphate–binding pocket, and the inserted residues form a wedge at the end of the C helix that promotes the active kinase conformation …
学术搜索中的文章
H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo… - Science translational medicine, 2013